pharmaceutical deals

Actionable Insights Powered by AI

GSK Expands Lupus Portfolio with $300M Upfront Deal for T-Cell Engager

GSK, lupus, T-cell engager, Chimagen Biosciences, autoimmune diseases, pharmaceutical deals